Investigation and Development of the BODIPY-Embedded Isotopic Signature for Chemoproteomics Labeling and Targeted Profiling
Journal of the American Society for Mass Spectrometry · 2024
DOI: 10.1021/jasms.4c00246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society for Mass Spectrometry, 2024. Verfasst von Rachel Joshi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia 23219, United States. Hauptthemen laut MEDLINE: Boron Compounds, Proteomics, Click Chemistry. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
A common goal in mass spectrometry-based chemoproteomics is to directly measure the site of conjugation between the target protein and the small molecule ligand. However, these experiments are inherently challenging due to the low abundance of labeled proteins and the difficulty in identifying modification sites using standard proteomics software. Reporter tags that either generate signature fragment ions or isotopically encode target peptides can be used for the preemptive discovery of labeled peptides even in the absence of identification. We investigated the potential of BODIPY FL azide as a click chemistry enabled chemoproteomics reagent due to the presence of boron and the unique 1:4 natural abundance ratio of 10B:11B. The isotopes of boron encode BODIPY-labeled peptides with a predictable pattern between the monoisotopic (M) and M+1 peaks. BODIPY-labeled peptides were identified in MS1 spectra using an R script that filters for the signature 10B:11B intensity ratio and mass defect. Application of the boron detection script resulted in three times the labeled peptide coverage achieved for a BODIPY-conjugated BSA sample compared with untargeted data-dependent acquisition sequencing. Furthermore, we used the inherent HF neutral loss signature from BODIPY to assist with BODIPY-modified peptide identification. Finally, we demonstrate the application of this approach using the BODIPY-conjugated BSA sample spiked into a complex E. coli. digest. In summary, our results show that the commercially available BODIPY FL azide clicked to alkyne-labeled peptides provides a unique isotopic signature for pinpointing the site(s) of modification with the added potential for on- or off-line UV or fluorescence detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia 23219, United States.
- Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia 23298-0533, United States.
ORCID-Profile: Adam M Hawkridge
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- National Heart, Lung, and Blood Institute
- Virginia Commonwealth University
Zitieren
APA
Joshi, R., & Hawkridge, A. M. (2024). Investigation and Development of the BODIPY-Embedded Isotopic Signature for Chemoproteomics Labeling and Targeted Profiling. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00246
Vancouver
Joshi R, Hawkridge AM. Investigation and Development of the BODIPY-Embedded Isotopic Signature for Chemoproteomics Labeling and Targeted Profiling. Journal of the American Society for Mass Spectrometry. 2024. doi:10.1021/jasms.4c00246
BibTeX
@article{Joshi2024,
author = {Joshi, Rachel and Hawkridge, Adam M},
title = {Investigation and Development of the BODIPY-Embedded Isotopic Signature for Chemoproteomics Labeling and Targeted Profiling},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2024},
doi = {10.1021/jasms.4c00246}
}
EUVIMED